ILK and chronic myelogenous leukemia, BCR-ABL1 positive: Our data suggest that administration of fibronectin—or an increase of fibronectin levels via inhibition of ILK—may be beneficial in BCR-ABL1T315I+ CML, for which limited therapies or only treatments with significant side effects exist.